Introduction
In previous studies we have demonstrated a difference in the mode of action of prostaglandin E2 versus oxytocin during induced parturition: prostaglandin Ei gave a slower onset of contractions [2] and induced a parturition time dependent decrease in maternal serum prolactin levels [3] . Prostaglandin p2a elevates maternal serum prolactin concentrations [7] and is a potent stimulator of uterine contractions [5] . Some investigators suggest that prostaglandin Fia is formed in the uterus during contractions [16, 17, 28] . If this prostaglandin reaches the circulation one would expect an increase in maternal serum prolactin. However, the scarce data available from spontaneous labor rather indicate a decrease in serum prolactin during parturition [9, 15, 31, 32] .
For reasons discussed in detail by GRANSTRÖM et al. [14] , primary prostaglandins cannot be measured accurately in blood plasma samples. The major PGE 2 metabolite, 15-keto-13,14-dihydroprostaglandin Ei, is rearranged and its analysis requires special conditions [13] . The corresponding PGF2a metabolite, 15-keto-13,14-dihydroprostaglandin F2a, can be determined in plasma and reflects the formation of F-prostaglandins [12] . Accordingly, it was selected for assay in the present communication. To explore whether changes in 15-keto-13,14-dihydroprostaglandin F2a levels in maternal blood during induced parturition are related to serum prolactin changes, the present study was undertaken.
Materials and methods
The study comprised 83 healthy women in whom labor was induced mainly for reasons of post-datism (table I). All patients had a vertex presentation and a normal pelvic outlet. Patients with toxemia of pregnancy treated with more than 100 mg hydralazine (Apresoline®, CIBA) and/or 1 g chlortiazide (Chlortride®, MSD) daily were excluded from the study, as were patients with any other disease.
Labor was induced by low amniotomy and intravenous infusion of oxytocin (Syntocinon®, Sandoz) in 5.5% glucose, starting at 8.30 a.m. with 5 mlU/min and increasing over three hours to a maximum of 20 mlU/min; or by low amniotomy and oral administration of PGEi (Upjohn Co., Kalamazoo, Mich., USA): dosage 0.5 mg initially, followed by 1.0 mg every hour until delivery. Treatment was randomized. The registration of uterine contractility was done with external and internal tocography according to established procedures [27] . Start of labor was defined as the time when three contractions with an amplitude of more than 25 mm Hg Blood samples were drawn from the antecubital vein at the start of treatment, one hour into treatment, immediately prior to delivery and after delivery. Mixed umbilical blood was collected at parturition by section of the cord. Serum and plasma were isolated by centrifugation and stored at -20 °C until analyzed. The number of individuals from whom a complete set of analyzes could be obtained was few. Therefore, the results given in tables II to IV refer to patients in whom the appropriate samples were obtained to allow intra-patient comparisons. Radioimmunoassay (RIA) of serum samples was performed in duplicate with commercial kits from Serono Diagnostics (prolactin) and Diagnostic Products Corp. (cortisol). Intraassay and interessay coefficients of variation were all below 10%. Levels of 15-ketodihydroPGF2a in plasma were determined by RIA as described in detail previously [12] . Specificity of the employed antiserum and accuracy data have been reported previously [26] .
The study also included eight non-pregnant healthy women with normal menstrual cycles. These women were given a single dose of 0.5 mg PGE2 orally. Blood was sampled after 10, 20, 30, 60 and 90 minutes. Levels of 15-ketodihydro-PGFia were determined as described above.
Statistical methods:
Calculations were proformed on the logarithms of the measured values. Two-tailed 95% conficence intervals of the mean in terms of logarithmic values were calculated. Probability values (p-values) were determined in two-tailed tests. Geometric means and interval limits were obtained from the antilogarithms. When variances of two groups differed significantly, a separate variance estimate of Student's t-statistic was used, otherwise a pooled variance estimate, to test whether the means of the groups differed or not. Contrasts of means between more than two groups were also calculated. Student's tstatistic was used to test whether the formed contrasts differed from expectancy.
Results
The changes in maternal serum hormone levels during induced parturition are displayed in table II. Oxytocin and PGEi caused similar elevations in maternal serum cortisol (data not shown): whereas, decreases in the levels of prolactin seemed more pronounced in the PGE2 group (table II) . The changes observed in 15-ketodihydro-PGFia throughout parturition were highly significant in both treatment groups. The PGEi group showed a significantly higher increase than the oxytocin group.
In terms of onset of contractions, the median time for women in the PGEi group was 62 minutes and for women in the oxytocin group 45 minutes (p = 0.004; median test). The total time to delivery did not differ between the groups (table I) . If onset of contractions is related to elevation of 15-ketodihydro-PGF2a, this should be reflected one hour into treatment. Among women receiving oxytocin, the 15-ketodihydro-PGF2a level changed from 315 pmol/1 (226-439) to 361 pmol/1 (264-494) during the first hour of treatment (n = 31). This increase is not significant. In the PGE2 group (n = 31) the corresponding figures were 396 pmol/1 (282-556) and 821 pmol/1 (614-1096). The elevation in the PGE2 group is highly significant (p < 0.001; paired t-test). Tested for the contrast between the PGE2 and oxytocin groups, a significant difference was found (p < 0.001), i.e. the elevation in the PGE2 group was significantly higher than in the oxytocin group.
Following delivery, there was still a difference between PGE2 and oxytocin treated women in terms of 15-ketodihydro-PGF2a levels in maternal plasma; whereas, no significant difference was seen either in prolactin (table III) or in cortisol concentrations (data not shown). The level of 15-ketodihydro-PGF 2a in the mixed umbilical plasma in each treatment group was almost the same as in the maternal plasma immediately prior to delivery. When the two experimental groups were compared for hormone levels in mixed umbilical blood (table IV) , a clearly significant difference was observed in 15-ketodihydro-PGF2a concentration but not in prolactin.
The non-pregnant women responded to oral PGE2 with an increase in levels of 15-keto-13,14-dihydro-PGF2a which was already significant at 10 (p = 0.034; Wilcoxon) and 20 minutes (p = 0.012; Wilcoxon) after PGE2 administration. The mean basal level was 160 pmol/1 (129-218) and after PGE 2 administration 228 pmol/1 (118-297) and 440 pmol/1 (213-907) at 10 and 20 minutes, respectively. One hour after treatment the average concentration was 476 pmol/1 (324 -605), i.e. no significant in- crease occurred between 20 and 60 minutes. None of the women experienced uterine contractions or complained of abnormal pain and after 90 minutes the average plasma level was still elevated, i.e. 543 pmol/l (409-789) (figure 1).
Discussion
The present report shows that oral PGE2 treatment leads to increases in the plasma content of 15-ketodihydro-PGF2a that are clearly above the levels induced by oxytocin and reportedly at hand during spontaneous labor [29, 36] . Yet, contractions appeared later in the PGEz treated group. The average time before contractions appeared in the PGE2 treated pregnant women was 62 minutes. The women receiving oxytocin had a mean time to onset of contractions of 45 minutes but no increase in plasma concentrations of 15-ketodihydro-PGF2a at 60 minutes. From two hours into treatment to the time immediately before parturition there was no significant difference in the increase in plasma 15-ketodihydro-PGF2a between PGE2 and oxytocin treated women. Thus, the present study fails to relate increases in plasma levels of 15-ketodihydro-PGF2a to onset of uterine contractions [10, 21] . Nor was it possible to find a relation between the plasma concentration of the metabolite and delivery time [33] . The triggering of contractions may have been mediated by amniotomy and the locally formed prostaglandins may not have been reflected in the circulation [34, 35] . Once labor had been established, increases in plasma 15-ketodihydroPGF2a levels were similar in PGE2 and oxytocin treated women. In spontaneous labor it has been reported that 15-ketodihydro-PGF2a increased in parallel with cervical dilatation [16, 24] , possibly reflecting formation of uterine PGP2a. However, it has been questioned whether local formation of PGF2a in the uterus is soon reflected by 15-ketodihydrp-PGF2a in plasma [25, 30] . Oral PGE 2 obviously led to an increase in plasma levels of 15-ketodihydroPGP2a. A possible explanation is that PGE2 itself may be converted to PGF2a in the course of, or following, absorption [8, 18, 19, 20] and later be metabolized into 15-ketodihydroPGP2a. This metabolite lacks biological activity and cannot be related as such to the clinical events or to prolactin levels. Thus, high levels of this metabolite caused by exogenous PGE2 will shadow an endogenous production. Also in the case of non-pregnant women, a significantly elevated level of 15-ketodihydro-PGF2a metabolite is seen 20 minutes after oral PGE2. The levels remained high for as long as 90 minutes and, considering the short half-lives of PGE2 and PGF2a as well as of 15-ketodihydro-PGF2a in the circulation, it seems likely that exogenous PGE2 is not only converted to PGF2a but may also have induced an ongoing endogenous prostaglandin -i.e. PGF2a -biosynthesis, perhaps in the uterus. An alternative hypothesis for our findings is that an excess of PGE2 and its circulating metabolites could well overload enzyme systems to such an extent that this results in a longer circulating half-life of the PGF 2a metabolites [11] .
Since PGF2a and PGE2 exert antagonistic effects on prolactin levels in pregnant women [4, 7] , the lowering of prolactin during oral PGE2 therapy indicates that PGE2 effects dominate over PGF2a effects, even though £2 to some extent is converted to PGFia or induces PGFia biosynthesis. Since the stress of labor measured as serum cortisol (data not shown) was the same in both oxytocin and PGE2 treated women, this factor is likely not directly involved in prolactin release, as previously suggested [38] .
The possibility exists that the epidural analgesia might have influenced circulating prolactin and 15-ketodihydro-PGF 2a levels [22, 23, 37] . But the relative frequency of this therapy was very similar in the two treatment groups. It is thus less likely that epidural analgesia influenced our results.
About half an hour after delivery, maternal serum prolactin levels were the same in both treatment groups, indicating that the PGEi induced effects on maternal pituitary prolactin release had stopped or been counteracted. However, 1 S-ketodihydro-PGFia levels were at least as high some 30 minutes after as before delivery, which makes it less likely that 15-ketodihydro-PGF2a in itself participates in maternal pituitary prolactin release. The levels of 15-ketodihydro-PGF2a in the mixed umbilical cord blood seem to be close to the maternal plasma concentration in both treatment groups.
Since there is no artero-venous difference in umbilical blood for 15-ketodihydro-PGF 2a [1] , a maternal origin for the 15-ketodihydroPGF2<x measured in mixed umbilical blood may be suggested. The data also indicate that the placenta does not metabolize 15-ketodihydroPGF2a to any major extent.
In conclusion, our data show that there was no correlation between 15-keto-13,14-dihydroPGF2a concentration and onset of contraction or labor time in either the PGE2 or the oxytocin treated group. The higher values of plasma 15-keto-13,14-dihydro-PGF2a in women receiving PGE2 tablets as compared to those treated with oxytocin suggest that exogenous PGE2 is to some extent reduced to PGF2a. Such a reduction seems also to take place in non-pregnant women, in whom administration of oral PGE2 gave rise to marked increases in plasma 15-keto-13,14-dihydro-PGF2a. The marked decrease in serum prolactin in the PGE2 treated pregnant women, which normalized following parturition, suggests a PG involvement in serum prolactin control.
Summary
15-keto-13,14-dihydroprostaglandin p2a plasma levels were measured in pregnant women following labor induction with either oral PGE2 treatment or intravenous oxytocin, both combined with amniotomy. The median time to start of contractions was 62 minutes in the PGE2 treated group and 45 minutes in the oxytocin treated group (p < 0.01; median test). The increase in 15-ketodihydro-PGF2a appeared earlier in the PGEa group but not in the oxytocin group (p < 0.001 and p = 0.210, respectively). At delivery, the 15-ketodihydroPGF2a values had further increased in both treatment groups. The increase was significantly higher in the PGE2 treated patients compared with oxytocin treated patients (p = 0.03; contrast test). Despite higher 15-ketodihydro-PGF2a concentrations throughout parturition, PGE2 women did not deliver more rapidly than oxytocin infused women. There was no correlation between 15-ketodihydro-PGF2a blood concentrations and either onset of contrations or labor time. The decrease in maternal serum prolactin concentration during parturition was pronounced (p < 0.001) in the PGE2 group but occurred also in oxytocin treated patients (p < 0.02). A single oral dose (0.5 mg) of PGE 2 taken by non-pregnant women led to significant (p < 0.05) increases in 15-ketodihydro-PGF2a levels in blood plasma after 10 minutes. This increase persisted for at least 90 minutes. It is suggested that oral PGE2 may be transformed into PGF2a and/or induce endogenous PGF2 a biosynthesis.
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